EXACT Therapeutics AS: Primary insider notification

In connection with the appointment of Jonathan Allis to the board of directors of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been granted 63,263 options in the Company which will vest on a quarterly basis. Please see the attached notification form for further information. This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Per Walday, CEO EXACT Therapeutics Email per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com